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the tumour uptake of WX-554. In vivo efficacy studies 
revealed that the combination of WX-037 and WX-554 was 
non-toxic and exhibited marked tumour growth inhibition 
greater than observed with either agent alone.
Conclusion These studies show for the first time that com-
bination treatment with the novel MEK inhibitor WX-554 
and the novel PI3K inhibitor WX-037 can induce syn-
ergistic growth inhibition in vitro, which translates into 
enhanced anti-tumour efficacy in vivo.
Keywords PI3K · MEK · Combination · Synergy; 
Colorectal cancer
Introduction
The development of numerous targeted small molecule 
inhibitors represents an important and evolving new 
approach to cancer therapy. However, as tumours often 
have defects in multiple oncogenic signalling pathways, 
single agent anti-tumour activity is modest, and thus com-
binations of targeted agents are being investigated. Specifi-
cally, the MAPK pathway, a major proliferative pathway, 
and the PI3K pathway, a major survival pathway, are fre-
quently activated in cancer and are being concomitantly 
targeted.
Many MEK inhibitors, such as PD 0325901 and selu-
metinib (AZD6244), have been developed to target the 
MAPK pathway and have shown potent growth inhibi-
tory activity in experimental systems [1–4]. A novel 
orally available small molecule allosteric MEK inhibitor 
WX-554 (UCB1366554), which potently inhibits MEK1 
and MEK2 with a half maximal inhibitory concentration 
(IC50) of 4.7 and 11 nM, respectively, has been developed 
by Wilex and UCB Celltech. WX-554 has demonstrated 
Abstract 
Purpose Tumours frequently have defects in multiple 
oncogenic pathways, e.g. MAPK and PI3K signalling 
pathways, and combinations of targeted therapies may 
be required for optimal activity. This study evaluated the 
novel MEK inhibitor WX-554 and the novel PI3K inhibitor 
WX-037, as single agents and in combination, in colorectal 
carcinoma cell lines and tumour xenograft-bearing mice.
Methods In vitro growth inhibition, survival and signal 
transduction were measured using the Sulforhodamine B, 
clonogenic and Western blotting assays, respectively, in 
HCT116 and HT29 cell lines. In vivo anti-tumour efficacy 
and pharmacokinetic properties were assessed in HCT116 
and HT29 human colorectal cancer xenograft tumour-bear-
ing mice.
Results The combination of WX-554 and WX-037 exhib-
ited marked synergistic growth inhibition in vitro, which 
was associated with increased cytotoxicity and enhanced 
inhibition of ERK and S6 phosphorylation, compared to 
either agent alone. Pharmacokinetic analyses indicated 
that there was no PK interaction between the two drugs 
at low doses, but that at higher doses, WX-037 may delay 
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marked inhibition of ERK1/2 phosphorylation in HT29 
cells, and growth inhibition in a range of cell lines in vitro, 
and tumour growth delay or stasis in vivo, with increased 
sensitivity in BRAF or RAS mutant cells and tumours [5]. 
WX-554 has been shown to be safe and tolerable in a dose 
escalation study in healthy volunteers [6], and a recent 
Phase I study indicated that WX-554 has very good bio-
availability and that it is able to inhibit MEK signal trans-
duction in a dose-dependent manner [3, 7, 8]. WX-554 
was investigated in a Phase Ib/II dose escalation study to 
determine safety and pharmacokinetics/pharmacodynamics 
in patients with solid tumours [7, 9], which was terminated 
due to business, rather than clinical, reasons.
Targeting the PI3K/AKT pathway has been investigated 
with a range of PI3K inhibitors which can be isoform-
specific inhibitors, pan class I inhibitors (e.g. pictilisib, 
GDC-0941) or dual PI3K/mTOR inhibitors (e.g. dactolisib, 
NVP-BEZ235), and promising anti-cancer efficacy has 
been reported in pre-clinical models [10–16]. Wilex and 
UCB Celltech have also developed a novel small molecule 
pan class I PI3K inhibitor, WX-037 (UCB1370037), from 
an indole series. WX-037 is a potent inhibitor of the α and 
δ isoforms of PI3K (IC50 = 4.1 and 2.4 nM, respectively) 
and a weaker inhibitor of the β and γ isoforms of PI3K and 
DNA-PK (IC50 = 69, 36 and 28 nM, respectively) with no 
detectable inhibition of mTOR (IC50 = >20,000 nM). In 
pre-clinical studies, WX-037 demonstrated strong inhibi-
tion of AKT phosphorylation, and promising growth inhi-
bition in a range of cell lines in vitro, and tumour growth 
delay or stasis in vivo, with greater sensitivity observed 
in PIK3CA mutant or PTEN null cells and tumours [5]. 
WX-037 was investigated in a Phase I dose escalation study 
to investigate its safety, pharmacokinetics, pharmacody-
namics and clinical activity in patients with solid tumours; 
however, this trial was also terminated due to business rea-
sons [9, 17].
Previous studies have shown that concomitant inhibi-
tion of the PI3K and MAPK pathways by PI3K and MEK 
inhibition yields promising anti-cancer effects in vitro and 
in vivo [2, 18–26], and the combination of WX-554 and 
WX-037 demonstrated synergy in vitro and increased effi-
cacy in vivo [5]. Consequently, the Phase I trial of WX-037 
was designed not just to investigate the efficacy of single 
agent WX-037, but also the combination of WX-554 and 
WX-037 [9].
The aim of this study was to determine the in vitro and 
in vivo activity of the novel MEK inhibitor WX-554 and the 
novel PI3K inhibitor WX-037, alone and in combination, in 
colorectal carcinoma cell lines and tumour xenograft-bear-
ing mice. These colorectal carcinoma cell lines (HT29 and 
HCT116) were used as they both contain KRAS/RAF and 
PI3K pathway mutations. The first objective was to deter-
mine the in vitro potency and efficacy of the compounds, 
alone and in combination, by measuring growth inhibition 
using an SRB assay, cytotoxicity via a clonogenic assay 
and cell signalling by Western blotting, and to investigate 
if the effects of the combinations on cell growth were syn-
ergistic, additive or antagonistic using median effect analy-
ses. These results were then used to design in vivo experi-
ments to investigate the pharmacokinetic profile of the 
compounds and their efficacy, alone and in combination.
Methods
Ethics statement
All in vivo experiments were reviewed and approved by the 
Newcastle University (UK) animal welfare committee and 
were performed according to the guidelines for the welfare 
and use of animals in cancer research [27] and national law, 
under project license (PPL60/4442) issued by the UK Gov-
ernment Home Office under the animals (scientific proce-
dure) act 1986.
Inhibitors
The MEK inhibitor WX-554 and the PI3K inhibitor 
WX-037 were kindly supplied by Wilex, Munich, Ger-
many. For in vitro studies, the inhibitors were dissolved in 
anhydrous dimethyl sulphoxide (DMSO) and were stored 
frozen under light-protected conditions at −20 °C. For 
in vivo studies, the MEK inhibitor WX-554 was dissolved 
in 0.9% NaCl (w/v), 10 mM Na-citrate pH 3.0 (w/v) and 
0.2% Tween 20 (v/v) in sterile distilled water and the PI3K 
inhibitor WX-037 was suspended in SMEDDS (self-micro-
emulsifying drug delivery system; 25% Capmul MCM 
EP (glycerol monocaprylocaprate) (v/v), 37.5% Tween 
80 (polyoxyethylene(20) sorbitan monooleate) (v/v) and 
37.5% PEG 400 (polyethylene glycol 400) (v/v)).
Cell lines and reagents
HCT116 and HT29 human colorectal cancer cells were 
obtained from the ATCC (American Type Culture Collec-
tion). All cell lines were grown in RPMI-1640 medium 
(supplemented with 10% (v/v) foetal bovine serum, 1% 
(v/v) penicillin (50 U/ml)—streptomycin (50 mg/ml) and 
2 mM L-glutamine) and were confirmed free of myco-
plasma contamination by regular testing with Mycoalert 
(Cambrex, Iowa, USA).
Animals
Animal studies were all carried out using female athymic 
CD1 nude mice (Charles River, Kent, UK), implanted 
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with HCT116 or HT29 xenografts (1 × 107 cells in 50 µl 
media injected subcutaneously into the right flank), main-
tained and handled in isolators under specific pathogen-free 
conditions.
Growth inhibition assay
Exponentially growing cells were grown in media in 
96-well format and were exposed to increasing concentra-
tions of the single agent inhibitors WX-554 or WX-037, 
or WX-554 combined with WX-037 at 0.25, 0.5, 1, 2 or 
4 times their half maximal growth inhibitory concentra-
tion (GI50) in DMSO, or 0.5% DMSO alone, for 72 h. 
Growth was then measured using the Sulforhodamine B 
(SRB) method and analysed as described previously [23]. 
The GI50 concentration was calculated based on a standard 
point to point curve with 1000 segments using GraphPad 
Prism software (California, USA). The data were ana-
lysed by median effect analysis using CalcuSyn software 
(Biosoft, Cambridgeshire, UK), which calculates the com-
bination index of multiple drugs by an algebraic estimation 
algorithm.
Cytotoxicity assay
Exponentially growing cells were exposed to increas-
ing concentrations of the single agent inhibitors WX-554 
or WX-037, or 10 µM of WX-554 combined with 10 µM 
WX-037 in DMSO or 0.5% (v/v) DMSO alone for 72 h 
before harvesting and reseeding for colony formation. 
After growth for 10–14 days, colonies were fixed in metha-
nol–acetic acid 3:1 (v/v) and stained with crystal violet 
(0.4% w/v). Colonies consisting of more than 50 cells were 
counted on an automated colony counter (Oxford Optronix, 
Oxford, UK). Two-tailed paired t tests were used to com-
pare the different groups. Differences with a p < 0.05 were 
considered statistically significant.
Western blotting
Cells were treated with WX-554 and WX-037 at 1 or 10 
times the half maximal growth inhibitory concentration 
(GI50) in DMSO, or 0.5% (v/v) DMSO alone, for 24 h. 
Western blots were prepared, probed with phospho-4EBP1 
(Thr37/46) (#2855), phospho-p44/42 MAPK (Thr202/
Tyr204) (#4370), phospho-AKT (Ser473) (#4060) or phos-
pho-S6 ribosomal protein (Ser235/236) (#4858) monoclo-
nal antibodies obtained from Cell Signalling Technology 
(New England BioLabs (UK) Ltd, Hertfordshire, UK) and 
developed as described previously [23]. Blots were then 
stripped (100 mM 2-mercaptoethanol, 2% (w/v) SDS and 
62.5 mM Tris pH6.8 at 55 °C for 30 min) and re-probed 
with the respective total monoclonal antibody (4EBP1 
(53H11) (#9644), p44/42 MAPK (ERK1/2) (#4695), AKT 
(pan) (C67E7) (#4691) or S6 ribosomal protein (5g10) 
(#2217)) obtained from Cell Signalling Technology (New 
England BioLabs (UK) Ltd, Hertfordshire, UK) and devel-
oped as described above.
Pharmacokinetic (PK) studies
Mice bearing HCT116 or HT29 human tumour xenografts 
were treated with 1 or 5 mg/kg WX-554, or 20 or 100 mg/
kg WX-037, alone or in combination, and were bled by 
cardiac puncture under terminal anaesthesia at 6 or 24 h 
post-treatment (3 mice/time point). Blood was collected 
into heparinized tubes, and plasma was separated and 
stored at −20 °C until analysed. Tumours were removed, 
snap frozen in liquid nitrogen and stored at −80 °C prior 
to PK analyses. Samples were extracted with solid phase 
extraction (SPE) and analysed with high-performance liq-
uid chromatography (HPLC) coupled with tandem mass 
spectrometry (MS/MS) by Wilex (Munich, Germany). The 
quantification limit for WX-554 was 1 ng/mL and within 
and between day variation was <15%. WinNonlin Software 
Version 4.0.1 (Pharsight Corporation, Peypin, France) was 
used for PK/PD modelling and non-compartmental analy-
sis. Paired t tests were used to compare the different treat-
ment groups, and differences with a p value ≤0.05 were 
considered statistically significant.
Determination of anti‑tumour activity
Mice bearing HCT116 human tumour xenografts were 
randomized into treatment groups and then treated by 
oral gavage with either the vehicle (10 ml/kg), 2 mg/kg 
WX-554, 50 mg/kg WX-037 or the combination of 2 mg/
kg WX-554 and 50 mg/kg WX-037 once daily for 14 days. 
Tumour volume was monitored by calliper measurement 
using the equation a2 × b/2, where a is the smallest meas-
urement and b the largest. Data are presented as median 
relative tumour volumes (RTV), where the tumour volume 
in each mouse on the initial day of treatment (day 0) is 
assigned an RTV value of 1. The time to RTV4 for each 
individual tumour was calculated based on a standard 
point to point curve with 1000 segments using GraphPad 
Prism software (CA, USA). Mann–Whitney U tests were 
used to compare the different groups, i.e., the control ver-
sus each treatment group, the single agents versus each 
other and each single agent versus their combination. Dif-
ferences with a p value ≤0.05 were considered statistically 
significant.
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Results
The PI3K inhibitor WX‑037 and the MEK inhibitor 
WX‑554 are synergistic and exhibit increased 
cytotoxicity in combination in vitro
The growth inhibitory activity of the PI3K inhibitor 
WX-037 and the MEK inhibitor WX-554, as single agents, 
in HCT116 and HT29 cells was measured using the SRB 
assay (Supplementary Figure 1). Both drugs induced over 
65% growth inhibition in both the colorectal cell lines. The 
results were used to determine the half maximal growth 
inhibitory (GI50) concentration of the drugs after 72-h 
exposure. The MEK inhibitor WX-554 was found to have 
GI50 values of 38 and 4.3 nM, whereas the PI3K inhibi-
tor WX-037 was less potent with GI50 values of 2934 and 
112 nM in the HCT116 and HT29 cell lines, respectively 
(Supplementary Figure 1).
Studies were then performed to determine the effect 
of combining the PI3K and MEK inhibitors on colorectal 
carcinoma cell growth over 72 h. WX-037 and WX-554 
were used alone at 0.25x, 0.5x, 1x, 2x and 4x their respec-
tive GI50 concentration, as calculated from Supplementary 
Figure 1, and at equipotent concentrations at the same GI50 
ratios in combination. Figure 1 shows that the combination 
of WX-037 and WX-554 was markedly more growth inhib-
itory than either compound alone, completely inhibiting 
growth at the highest concentrations. Data were then evalu-
ated by median effect analysis (CalcuSyn, Biosoft, Great 
Shelford, UK) to determine whether the greater growth 
inhibitory activity of the combination of WX-554 and 
WX-037 reflected an additive or a synergistic effect. The 
combination of the PI3K inhibitor WX-037 and the MEK 
inhibitor WX-554 was strongly synergistic when combined 
at the GI50 concentration compared to the compounds alone 
(Supplementary Table 1).
Cell survival after 72-h exposure to the PI3K inhibitor 
WX-037 and the MEK inhibitor WX-554 was also meas-
ured using a clonogenic cytotoxicity assay. Single agent 
WX-554 showed significant cytotoxicity at 10 µM with 
67% cell kill in the HCT116 cell line and 75% in the HT29 
cell line; however, the mean lethal concentration (LC50) of 
0.6 µM and 1.6 µM WX-554 was approximately 16-fold 
and 372-fold higher than the corresponding GI50- values 
in the HCT116 and HT29 cell lines, respectively. WX-037 
showed no marked cytotoxicity with less than 50% cell 
death after 72 h treatment at 10 µM (Supplementary 
Figure 2).
The cytotoxicity of the PI3K and MEK inhibitors in 
combination after 72 h treatment was then determined. 
However, as WX-037 did not produce > 50% cytotoxicity 
at 10 µM, it was not possible to determine an LC50 value, 
and hence the highest concentration previously used of 
10 µM WX-037 was combined with 10 µM WX-554. There 
was a statistically significant increase in cytotoxicity when 
the PI3K and MEK inhibitors were combined, compared 
to the cytotoxicity induced by the drugs as single agents, 
in the HCT116 (p = 0.02) and HT29 (p < 0.01) cell lines 
(Fig. 2). Overall, the interaction of WX-037 and WX-554 
resulted in significantly enhanced cell growth inhibition 
and an increase in cytotoxicity in both cell lines studied.
The effect of 24-h exposure to the PI3K inhibitor 
WX-037 and the MEK inhibitor WX-554, both as sin-
gle agents and in combination, was also investigated by 
Western blotting to determine the effect on the PI3K/AKT 
signalling pathway, using total and phospho-specific anti-
bodies for AKT, S6 and 4EBP1 and the effect on MAPK 
signalling, using total and phospho-specific antibodies for 
Fig. 1  Growth inhibition induced by the PI3K inhibitor WX-037 
and the MEK inhibitor WX-554, alone and in combination, in the 
HCT116 and HT29 cell lines. HCT116 (a) and HT29 (b) cells were 
treated with the indicated fractions of the GI50 concentrations of the 
inhibitors, alone or in combination, derived from Supplementary 
Figure 1, for 72 h, and an SRB assay was subsequently performed. 
Growth is presented as a percentage of the control, in which cells 
were treated with 0.5% (v/v) DMSO. Points represent the mean of 
3 independent experiments ± standard error. Lines were fitted using 
nonlinear regression analysis
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ERK1/2. The compounds were used as single agents or in 
combination at their respective GI50 concentrations and at 
10x the GI50 concentration.
Supplementary Figure 3 shows that treatment with the 
MEK inhibitor WX-554 reduced ERK1/2 phosphorylation 
at 1 and 10 times the GI50 concentration in the HCT116 
cell line, and at 10 times the GI50 concentration in the 
HT29 cell line. The reduction in ERK1/2 phosphoryla-
tion was enhanced with the combination of WX-554 and 
WX-037 leading to complete inhibition with 10 times the 
GI50 concentration in both colorectal carcinoma cell lines 
(Supplementary Figure 3). Additionally, there was a con-
centration-dependent reduction in AKT phosphorylation in 
the HCT116 cell line after treatment with the single agent 
PI3K inhibitor WX-037 which was enhanced, to yield com-
plete inhibition at the GI50 concentration, after combined 
WX-037 and WX-554 treatment. In the HT29 cell line, 
there was a reduction in AKT phosphorylation at 10 times 
the GI50 concentration; however, this reduction was similar 
with single agent WX-037 and the combination (Supple-
mentary Figure 3).
Single agent WX-037 also caused a concentration-
dependent reduction in S6 phosphorylation at 1 and 10 
times the GI50 concentration, and treatment with the com-
bination of WX-037 and WX-554 enhanced this inhibition, 
causing complete inhibition at 10 times the GI50 concentra-
tion in both colorectal carcinoma cell lines (Supplementary 
Figure 3). However, WX-037 had no marked effect on the 
phosphorylation of 4EBP1 alone or in combination with 
WX-554 in either colorectal carcinoma cell line (Supple-
mentary Figure 3). Hence, overall, the combination of the 
MEK inhibitor WX-554 and the PI3K inhibitor WX-037 
resulted in enhanced inhibition of ERK1/2 and S6 phos-
phorylation, and inhibition of AKT phosphorylation, in 
both colorectal carcinoma cell lines. However, both the 
single agents and the combination had no major impact on 
4EBP1 phosphorylation.
The PI3K inhibitor WX‑037 and the MEK inhibitor 
WX‑554 exhibit increased tumour growth delay 
in combination in vivo
A PK study was carried out with samples taken 6 and 
24 h after treatment with a single dose of the PI3K inhibi-
tor WX-037 and the MEK inhibitor WX-554, alone and in 
combination, in HCT116 and HT29 human tumour xeno-
graft-bearing mice. The concentrations of the drugs in the 
plasma and the tumour tissue were measured using LC–
MS/MS (Figs. 3, 4, Supplementary Figures 4 and 5 and 
Supplementary Table 2).
Fig. 2  Cell survival after 72-h exposure to 10 µM of the PI3K inhibi-
tor WX-037 and 10 µM of the MEK inhibitor WX-554, alone and in 
combination, in the HCT116 cell line and HT29 cell lines. HCT116 
(a) and HT29 (b) cells were treated with a fixed concentration of each 
inhibitor alone or in combination for 72 h, and cell survival was sub-
sequently determined by clonogenic assay after 10–14 days of colony 
growth. Survival is presented as a percentage of the control, in which 
cells were treated with 0.5% (v/v) DMSO. Bars represent the mean 
of 3 independent replicates ± standard error. *Significantly different 
from either agent alone, p ≤ 0.05
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After a single dose of 1 or 5 mg/kg WX-554, alone or 
in combination with 20 or 100 mg/kg WX-037, WX-554 
concentrations in the plasma and tumour tissue gener-
ally greatly exceeded the in vitro GI50 value of 18 ng/ml 
(38 nM) in the HCT116 cell line and 2 ng/ml (4 nM) in 
the HT29 cell line (determined in Supplementary Fig-
ure 1) (Fig. 3, Supplementary Figure 4 and Supplemen-
tary Table 2A). The exception to this was that plasma 
WX-554 concentrations were only approximately equal 
to the HCT116 GI50 value at 6 h and were below the 
HCT116 GI50 value by 24 h, in the HCT116 tumour xen-
ograft-bearing mice after treatment with 1 mg/kg WX-554, 
alone or in combination with 20 or 100 mg/kg WX-037 
(Supplementary Figure 4A and Supplementary Table 2A). 
Additionally, the plasma WX-554 concentration was 
also below the HCT116 GI50 value by 24 h after 5 mg/
kg WX-554 alone; however, WX-554 concentrations still 
exceeded the GI50 value when 5 mg/kg WX-554 was com-
bined with WX-037 (Supplementary Figure 4C and Supple-
mentary Table 2A). However, overall, the absolute plasma 
and tumour levels of WX-554 were generally similar in the 
HT29 and HCT116 tumour xenograft-bearing mice (Fig. 3, 
Supplementary Figure 4 and Supplementary Table 2A).
There was no consistent effect of concomitant dosing 
with 20 or 100 mg/kg WX-037 on the levels of WX-554 
in the tumour or the plasma after administration of 1 mg/
Fig. 3  Concentrations of the MEK inhibitor WX-554 alone and in 
combination with the PI3K inhibitor WX-037 in tumours from mice 
bearing HCT116 or HT29 human tumour xenografts. Tumour con-
centrations of WX-554 measured by LC–MS/MS from HCT116 (a, 
c) and HT29 (b, d) tumour xenograft-bearing mice at the indicated 
time points after a single p.o. dose of 1 mg/kg (a, b) or 5 mg/kg (c, 
d) WX-554 alone or combined with 20 or 100 mg/kg WX-037. Data 
are presented as the mean concentration from 3 mice in each group ± 
standard error. Horizontal dashed lines indicate the in vitro GI50 con-
centration for the respective cell line, calculated from Supplementary 
Figure 1
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kg WX-554 in either HCT116 or HT29 tumour xeno-
graft-bearing mice. In contrast, after dosing with 5 mg/kg 
WX-554, there was generally a WX-037 dose-dependent 
decrease in the levels of WX-554 at 6 h in the tumour and 
the plasma upon concomitant treatment with WX-037, 
which was significant for the tumour data at 6 h (p < 0.05) 
(Fig. 3, Supplementary Figure 4 and Supplementary 
Table 2A). These results suggest that WX-037 may delay 
the tumour uptake of WX-554 at the higher dose (5 mg/kg) 
compared to when WX-554 is administered alone.
In contrast to the data for WX-554, after treatment 
with 20 mg/kg WX-037, as a single agent or in combina-
tion with 1 or 5 mg/kg WX-554, WX-037 concentrations 
in plasma and tumour tissue at 6 and 24 h were markedly 
lower than the in vitro GI50 value of 1414 ng/ml (2934 nM) 
in the HCT116 cell line (determined in Supplementary Fig-
ure 1) (Fig. 4a, Supplementary Figure 5A and Supplemen-
tary Table 2B). Plasma and tumour WX-037 concentrations 
were also markedly below the HCT116 GI50 value 24 h 
after treatment with 100 mg/kg WX-037, given as a single 
Fig. 4  Concentrations of the PI3K inhibitor WX-037 alone and in 
combination with the MEK inhibitor WX-554 in tumours from mice 
bearing HCT116 or HT29 human tumour xenografts. Tumour con-
centrations of WX-037 measured by LC–MS/MS from HCT116 (a, 
c) and HT29 (b, d) tumour xenograft-bearing mice at the indicated 
time points after a single p.o. dose of 20 mg/kg (a, b) or 100 mg/kg 
(c, d) WX-037 alone or combined with 1 or 5 mg/kg WX-554. Data 
are presented as the mean concentration from 3 mice in each group ± 
standard error. Horizontal dashed lines indicate the in vitro GI50 con-
centration for the respective cell line, calculated from Supplementary 
Figure 1
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agent or in combination with 1 or 5 mg/kg WX-554; how-
ever, concentrations in the plasma and tumour tissue were 
similar to or exceeded the HCT116 GI50 value 6 h after a 
100 mg/kg dose of WX-037 (Fig. 4c, Supplementary Fig-
ure 5C and Supplementary Table 2B).
After treatment with 20 or 100 mg/kg WX-037, as a sin-
gle agent or in combination with 1 or 5 mg/kg WX-554, 
concentrations in plasma and tumour tissue greatly 
exceeded the in vitro GI50 value of 54 ng/ml (112 nM) in 
the HT29 cell line (determined in Supplementary Figure 1) 
at 6 h. At 24 h, although concentrations were similar to or 
exceeded the HT29 GI50 value in all tumour samples and 
in plasma after a 100 mg/kg dose of WX-037, plasma con-
centrations had generally declined to below the GI50 value 
after a 20 mg/kg dose of WX-037 (Fig. 4b–d, Supplemen-
tary Figure 5B and D and Supplementary Table 2B). As 
with the WX-554 data, the absolute plasma and tumour 
levels of WX-037 were similar in the HCT116 and HT29 
tumour xenograft-bearing mice (Fig. 4, Supplementary Fig-
ure 5 and Supplementary Table 2B).
There did not appear to be a consistent effect of con-
comitant dosing with 1 or 5 mg/kg WX-554 on the levels 
of WX-037 in the tumour or the plasma at 6 h after dos-
ing with 20 mg/kg in either HCT116 or HT29 tumour xen-
ograft-bearing mice (Fig. 4a, b, Supplementary Figure 5A 
and B and Supplementary Table 2B). However, after dos-
ing with 100 mg/kg, there appeared to be a dose-depend-
ent decrease in the levels of WX-037 in the tumour and 
the plasma upon concomitant dosing with WX-554 at 6 h, 
but this effect was only significant in HCT116 tumours 
(Fig. 4c, d, Supplementary Figure 5C and D and Supple-
mentary Table 2B). Hence, concentrations of WX-037 were 
generally similar regardless of whether it was administered 
as a single agent or in combination with WX-554, and lev-
els were consistently higher at 6 h compared with 24 h.
As the combination of WX-554 and WX-037 was syn-
ergistic in the in vitro studies, it may not be necessary for 
the drug concentrations in the plasma and the tumour to 
exceed those of the in vitro GI50 values for the single agents 
to achieve efficacy with the combination in vivo. Based on 
the in vitro results, in order to achieve half maximal growth 
inhibition, less than 1/6th and approximately 1/3rd of the 
single agent GI50 was required for 50% growth inhibi-
tion with the drug combination in the HCT116 and HT29 
cell lines, respectively, which equates to GI50 values of 3 
and <1 ng/ml WX-554 and 219 and 20 ng/ml WX-037 in 
the HCT116 and HT29 cell lines (calculated from Fig. 1). 
Therefore, with all the combinations of WX-554 and 
WX-037, WX-554 levels in the plasma and tumour tissues 
are at or exceed the GI50 concentration for the combination 
at both 6 and 24 h (Fig. 3, Supplementary Figures 4 and 
Supplementary Table 2A). Furthermore, with all combina-
tions of WX-554 and 100 mg/kg WX-037, WX-037 levels 
in the plasma and tumour tissues are at or exceed the GI50 
for the combination at both 6 and 24 h, and with all combi-
nations of WX-554 with 20 mg/kg WX-037, WX-037 levels 
in the plasma and tumour tissues are at or exceed the GI50 
for the combination at 6 h, but remain below at 24 h (Fig. 4, 
Supplementary Figure 5 and Supplementary Table 2B).
Based on the results of the PK study, the efficacy of 
50 mg/kg of the PI3K inhibitor WX-037 and 2 mg/kg of the 
MEK inhibitor WX-554 given orally, as single agents and 
in combination, was assessed in HCT116 human tumour 
xenograft-bearing mice (Fig. 5). The individual doses of 
the PI3K and MEK inhibitors were chosen to be approxi-
mately equiactive, in order to mirror the in vitro conditions 
under which synergy had been demonstrated (Supplemen-
tary Figure 1). In this study, mice were treated daily for 
14 days and tumour volumes were measured three times a 
week. Figure 5a demonstrates that treatment with 50 mg/kg 
WX-037 and 2 mg/kg WX-554, alone and in combination, 
caused tumour growth delay compared to vehicle-treated 
control tumours, and that growth delay was greater with 
the combination. Additionally, body weight was monitored 
daily to assess the tolerability of the therapy, and both sin-
gle agent and combination treatments were found to be well 
tolerated as average body weights did not drop below 89% 
of the starting weight (Fig. 5b). The time for the tumours to 
quadruple in size (time to RTV4) was calculated (Fig. 5c), 
and statistical analyses using a Mann–Whitney test dem-
onstrated a significant difference between vehicle-treated 
control tumours and the combination group (p < 0.01), and 
between the single agent MEK inhibitor and the combina-
tion group (p = 0.02).
Discussion
The novel PI3K inhibitor WX-037 and the novel MEK 
inhibitor WX-554 have demonstrated in vitro activity in a 
range of cancer cell lines including breast, fibrosarcoma, 
thyroid, melanoma, colorectal, ovarian and pancreas lines 
with a broad range of GI50 values, where generally the cell 
lines most sensitive to WX-037 had PIK3CA mutations 
or PTEN loss, and to WX-554 had BRAF or RAS muta-
tions [5]. Furthermore, the potency of WX-554 determined 
in the HCT116 and HT29 cell lines in this study (38 and 
4.3 nM, respectively) was similar to that determined in the 
unpublished Wilex studies (29 and 7.2 nM) [5], and to the 
MEK inhibitor, PD 0325901 (21 and 6.5 nM) using the 
same assay [23]. Similarly the potency of WX-037 deter-
mined here in the HCT116 and HT29 cell lines (2934 and 
112 nM, respectively) was similar to that reported in the 
unpublished Wilex studies (136 nM in the HT29 cell line) 
[5], and to the pan class I PI3K inhibitor, pictilisib (1081 
and 157 nM) using the same assay [23].
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In these in vitro studies, the HT29 colorectal carcinoma 
cell line was consistently more sensitive to WX-037 and 
WX-554 than the HCT116 cell line (26 and 9-fold differ-
ence, respectively), which is consistent with other studies 
where the HT29 cell line exhibited increased sensitivity 
to pan class I PI3K and/or MEK inhibition, compared to 
the HCT116 cell line [23, 28, 29]. The observed differ-
ence could be due to the presence of a BRAF, rather than 
a KRAS, mutation as RAS mutations have been associated 
with intrinsic resistance in a previous study [30]. Alterna-
tively, differences in cell signalling may be responsible, as 
sensitivity to MEK inhibition was found to correlate with 
strong ERK1/2 signalling and weak PI3K signalling [28]. 
Furthermore, the plethora of other mutations found in the 
HT29 and HCT116 cell lines may contribute to the differ-
ence in sensitivity [29, 31].
The combination of WX-037 and WX-554 was strongly 
synergistic, which is consistent with previous unpublished 
studies by UCB Celltech and Wilex where synergy was 
observed in the SK-MEL-28 melanoma, HT29 colorectal, 
Mia PaCa-2 pancreatic and SKOV-3 ovarian carcinoma 
cell lines [5]. The degree of synergy with the WX-037 and 
WX-554 combination was consistent with in vitro pub-
lished studies using combinations of other PI3K and MEK 
inhibitors [2, 18, 23, 24, 32, 33].
Single agent WX-554 not only exhibited growth inhibi-
tion but also significant cytotoxicity, albeit at higher con-
centrations with LC50 values approximately 16-fold and 
372-fold higher than the corresponding GI50− values in the 
HCT116 and HT29 cell lines, respectively. This marked 
cytotoxicity at 10 µM is in contrast to the effect of PD 
0325901 and selumetinib [23] and also to the general per-
spective that MEK inhibitors are cytostatic [34]. However, 
another study has already reported that selumetinib can 
cause apoptosis in some human tumour xenografts, but not 
in others, which was suggested to be due to differences in 
ERK1/2 substrate expression or differential cell signalling 
networks [35], and hence the result with WX-554 is not 
entirely unexpected.
In contrast to the effect of the MEK inhibitor, the PI3K 
inhibitor WX-037 at 10 µM showed only limited cytotox-
icity, which is consistent with the results observed with 
another pan class I PI3K inhibitor pictilisib [23]. However, 
the marked synergy observed in the growth inhibition stud-
ies with WX-037 and WX-554 translated into cytotoxic-
ity, albeit at a high concentration (10 µM), as there was a 
statistically significant increase in cytotoxicity with the 
combination of the Wilex PI3K and MEK inhibitors. This 
cytotoxicity is consistent with previous unpublished stud-
ies by UCB Celltech and Wilex where the observed growth 
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Fig. 5  Efficacy and tolerability of the PI3K inhibitor WX-037 and 
the MEK inhibitor WX-554 in mice bearing human HCT116 colo-
rectal tumour xenografts. HCT116 tumour xenografts were treated 
with either vehicle control, 2 mg/kg of the MEK inhibitor WX-554 
and 50 mg/kg of the PI3K inhibitor WX-037 alone, or 2 mg/kg of the 
MEK inhibitor WX-554 and 50 mg/kg of the PI3K inhibitor WX-037 
in combination, p.o. once daily for 14 days. a Tumour growth curves: 
data are presented as the median relative tumour volume (RTV), 
where the growth is calculated for each tumour relative to its size on 
day 0. Points represent the median of the 10 mice in each group. The 
dashed line shows the point at which tumours reached four times the 
initial volume (RTV4). b Effects on body weight: data are presented 
as a percentage of starting body weight. Points represent the mean of 
the mice in each group ± standard error. c Time taken for xenografts 
to reach four times the initial volume (time to RTV4): data are pre-
sented as the time taken by each individual tumour in each group to 
quadruple in size, and lines to represent the mean of the mice in each 
group ± standard error. p values are given where the combination is 
significantly different from either agent alone (p ≤ 0.05)
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inhibitory synergy with WX-037 and WX-554 in the SK-
MEL-28 melanoma, HT29 colorectal, Mia PaCa-2 pancre-
atic and SKOV-3 ovarian carcinoma cell lines was found 
to correlate with the induction of apoptosis [5]. Similarly, 
published in vitro studies have shown that combined inhibi-
tion of PI3K and MEK resulted in cell death [33, 36, 37].
Cell signalling studies showed that the single agent 
PI3K inhibitor WX-037 caused a concentration-dependent 
reduction in AKT and S6 phosphorylation, which was gen-
erally enhanced by the MEK inhibitor WX-554, but that 
4EBP1 phosphorylation was not inhibited, consistent with 
the results of published studies using pan class I PI3K, as 
opposed to mixed PI3K/mTOR, inhibitors [23, 32, 37, 38]. 
Furthermore, single agent MEK inhibitor WX-554 caused 
a concentration-dependent reduction in ERK phosphoryla-
tion, and the combination of WX-554 and WX-037 resulted 
in enhanced inhibition of ERK1/2 phosphorylation, as 
observed with other MEK inhibitors [23, 39, 40] and com-
binations [23, 33].
In the pre-clinical studies presented here, and in both 
pre-clinical and clinical studies reported elsewhere [5, 6], 
WX-554 has been shown to be non-toxic. Furthermore, sin-
gle agent WX-554 induced tumour growth delay at 2 mg/kg 
in HCT116 colorectal tumour xenograft models, consist-
ent with previous unpublished studies using WX-554 and 
published studies using other MEK inhibitors that reported 
tumour growth delay or stasis in vivo, with increased sen-
sitivity in BRAF or RAS mutant cells and tumours [3–5, 
25]. In vivo pharmacokinetic analyses revealed concentra-
tions of WX-554 in plasma and tumour tissue increased in 
a dose-dependent manner and that tumour WX-554 levels 
generally exceeded the in vitro GI50 concentration, whereas 
plasma levels were more variable.
Single agent WX-037 was also found to be non-toxic in 
these studies and those reported elsewhere [5, 17], which 
is consistent with data for other pan class I PI3K inhibi-
tors [41–45]. Furthermore, 50 mg/kg WX-037 generated a 
tumour growth delay in HCT116 colorectal tumour xeno-
graft models, which is consistent with previous unpub-
lished studies using WX-037 and published studies using 
other pan class I PI3K inhibitors that reported tumour 
growth delay, or in some cases tumour stasis, with greater 
sensitivity in PIK3CA mutant or PTEN null cells and 
tumours [5, 14, 15, 46–51]. Pharmacokinetic studies indi-
cated that concentrations of WX-037 in plasma and tumour 
tissue increased dose dependently and that WX-037 tumour 
and plasma levels generally exceeded the in vitro GI50 con-
centration at an early time point (6 h), depending on the 
cell line and dose, whereas levels generally had decreased 
below the GI50 value by the later time point (24 h). These 
pharmacokinetic data are similar to those observed in 
HCT116 tumour xenograft-bearing mice treated with pic-
tilisib [25].
The PK analyses indicated that there was no pharma-
cokinetic interaction between WX-037 and WX-554 at 
lower doses. However, concomitant dosing of WX-037 with 
the high dose (5 mg/kg) of WX-554 caused a dose-depend-
ent decrease in early time point (6 h) WX-554 tumour and 
plasma concentrations, and a dose-dependent increase in 
late time point (24 h) WX-554 levels, suggesting that the 
presence of WX-037 may delay the uptake of WX-554, 
leading to higher WX-554 levels at 24 h. Furthermore, con-
comitant WX-554 dosing with high doses (100 mg/kg) of 
WX-037 caused a dose-dependent decrease in early time 
point (6 h) WX-037 tumour and plasma concentrations; 
however, this effect was only significant in the HCT116 
tumour tissue due to variation in the data. The pharma-
cokinetic interaction between higher doses of WX-037 and 
WX-554 is in contrast to the results obtained with the com-
bination of PD 0325901 and pictilisib in HCT116 tumour 
xenograft-bearing mice [25], where there was no signifi-
cant pharmacokinetic interaction, and to pre-clinical and 
clinical reports that there was no pharmacokinetic interac-
tion between the PI3K and MEK inhibitors, pictilisib and 
cobimetinib [52, 53]. However, a recent Phase Ib study 
using a combination of the PI3K inhibitor buparlisib and 
the MEK inhibitor trametinib reported a potential pharma-
cokinetic interaction, which was suggested to be due to the 
variability of the accumulation of the MEK inhibitor as no 
clear mechanism could be identified [54].
In HCT116 colorectal tumour xenografts, the combi-
nation of 50 mg/kg WX-037 and 2 mg/kg WX-554 was 
non-toxic and caused tumour stasis and enhanced tumour 
growth delay compared to either single agent at the same 
dose. This improved activity is consistent with previous 
studies using combinations of PI3K and MEK inhibitors in 
a range of pre-clinical human tumour xenograft and mouse 
models [19, 21, 22, 25, 55–58]. In a previous study using 
the MEK inhibitor, PD 0325901, and the PI3K inhibitor, 
GDC-0941, the cell line-dependent differences in sensitiv-
ity to the inhibitors determined in the in vitro studies did 
not correlate with the results observed in the in vivo studies 
[23, 25], suggesting that HT29 xenografts would not neces-
sarily of been more sensitive to the inhibitors in vivo. Nev-
ertheless, previous studies by UCB and Wilex have dem-
onstrated that WX-554 treatment is able to induce tumour 
growth delay in HT29 xenografts [5].
The improved efficacy using combinations of PI3K and 
MEK inhibitors in pre-clinical studies is being translated 
into clinical trials [45, 54, 59], and there are currently at 
least 7 ongoing or completed Phase 1b clinical studies [9]. 
However, there have been issues with the tolerability of the 
combination treatment in two phase 1b trials combining the 
MEK inhibitor trametinib, with either the pan-PI3K inhibi-
tor buparlisib, or the PI3K/mTOR inhibitor GSK2126458, 
where the former study showed promising anti-tumour 
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activity but frequent dose interruptions and reductions were 
necessary due to toxicity [54]. The latter study was termi-
nated due to poor tolerability and efficacy [9, 60]. These 
results suggest that the choice of the PI3K and MEK inhib-
itor to be combined will be crucial to the success of the 
treatment, due to subtle differences in the pharmacology 
of the inhibitors leading to differing toxicity profiles. Over-
all, these studies characterize, for the first time, the in vitro 
and in vivo efficacy of the PI3K inhibitor WX-037 and the 
MEK inhibitor WX-554, as single agents and in combina-
tion. Furthermore, these studies illustrate that dual targeting 
of PI3K and MEK can induce synergy in vitro which trans-
lates to marked tumour growth delay in vivo.
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